Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Brentuximab”

177 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 177 results

Not applicableStudy completedNCT04998331
What this trial is testing

A Spanish Medical Record Review of Adults With Relapsed or Refractory CD30+ Malignancies When Re-treated With Brentuximab-vedotin

Who this might be right for
Hodgkin DiseaseLymphoma, T-Cell, Cutaneous
Takeda 51
Not applicableStudy completedNCT07171827
What this trial is testing

Anti-CD30 (Brentuximab Vedotin) With AVD Versus ABVD Chemotherapy Protocol Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

Who this might be right for
Anti-CD30BrentuximabDoxorubicin+4 more
Helwan University 60
Testing effectiveness (Phase 2)WithdrawnNCT04795869
What this trial is testing

Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma

Who this might be right for
Recurrent Angioimmunoblastic T-Cell LymphomaRecurrent Enteropathy-Associated T-Cell LymphomaRecurrent Follicular T-Cell Lymphoma+11 more
Northwestern University
Early research (Phase 1)WithdrawnNCT03373305
What this trial is testing

Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas

Who this might be right for
CD30-Positive Neoplastic Cells PresentFolliculotropic Mycosis FungoidesRecurrent Mycosis Fungoides+4 more
City of Hope Medical Center
Early research (Phase 1)Study completedNCT01950364
What this trial is testing

Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma

Who this might be right for
Hodgkin LymphomaAnaplastic Large-cell Lymphoma
Millennium Pharmaceuticals, Inc. 20
Large-scale testing (Phase 3)UnknownNCT06186986
What this trial is testing

CD30 Imaging in Diffuse Large B-cell Lymphoma

Who this might be right for
Diffuse Large B-cell-lymphoma
University Medical Center Groningen 20
Post-approval studies (Phase 4)Study completedNCT05442554
What this trial is testing

Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma

Who this might be right for
T-Cell Lymphoma
Takeda 10
Testing effectiveness (Phase 2)Study completedNCT01393717
What this trial is testing

Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma

Who this might be right for
Recurrent Hodgkin LymphomaRefractory Hodgkin Lymphoma
City of Hope Medical Center 57
Early research (Phase 1)WithdrawnNCT02780011
What this trial is testing

Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies

Who this might be right for
CD30-positive LymphomaCD30-positive Solid Tumor
Eric Bernicker, MD
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06925555
What this trial is testing

Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS

Who this might be right for
EBV-Positive Diffuse Large B-Cell Lymphoma, NosBrentuximab Vedotin
The First Affiliated Hospital with Nanjing Medical University 25
Testing effectiveness (Phase 2)Study completedNCT02505269
What this trial is testing

Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma

Who this might be right for
Hodgkin Lymphoma
Massachusetts General Hospital 34
Testing effectiveness (Phase 2)Study completedNCT01780662
What this trial is testing

Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma

Who this might be right for
Recurrent Adult Hodgkin LymphomaRecurrent Childhood Hodgkin LymphomaRefractory Childhood Hodgkin Lymphoma
National Cancer Institute (NCI) 46
Testing effectiveness (Phase 2)Ended earlyNCT02499627
What this trial is testing

Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage Setting

Who this might be right for
Lymphatic Diseases
Fondazione Italiana Linfomi - ETS 43
Testing effectiveness (Phase 2)Study completedNCT02686346
What this trial is testing

Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE

Who this might be right for
Hodgkin Disease
The Lymphoma Academic Research Organisation 53
Testing effectiveness (Phase 2)Study completedNCT02429375
What this trial is testing

Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma

Who this might be right for
Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center 7
Testing effectiveness (Phase 2)Looking for participantsNCT03356054
What this trial is testing

Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse

Who this might be right for
DLBCL
Stichting Hemato-Oncologie voor Volwassenen Nederland 37
Testing effectiveness (Phase 2)Active Not RecruitingNCT04609566
What this trial is testing

Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

Who this might be right for
MelanomaNon-small Cell Lung CancerSquamous Cell Carcinoma of the Head and Neck
Seagen, a wholly owned subsidiary of Pfizer 161
Testing effectiveness (Phase 2)Study completedNCT02927769
What this trial is testing

Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment

Who this might be right for
Hodgkin Disease
Bristol-Myers Squibb 72
Testing effectiveness (Phase 2)Looking for participantsNCT05039073
What this trial is testing

Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors

Who this might be right for
Recurrent Classic Hodgkin LymphomaRefractory Classic Hodgkin Lymphoma
Emory University 46
Testing effectiveness (Phase 2)UnknownNCT05006664
What this trial is testing

Brentuximab Vedotin in Combination With CHEP in Patient With PTCL

Who this might be right for
Lymphoma, T-Cell, Peripheral
Czech Lymphoma Study Group 33
Load More Results